Latest Headlines

  1. SGD Pharma Leads Pharma Packaging Innovation And Decarbonization At PharmaPack Europe 2026 1/28/2026

    SGD Pharma, a global market leader in pharmaceutical glass primary packaging and the leader of its industry on sustainability, will showcase its latest advancements in high-performance solutions at Pharmapack Europe, taking place in Paris on 21st to 22nd January 2026.

  2. Unravel Biosciences And The SCN2A Foundation Announce Drug Discovery Collaboration 1/28/2026

    The SCN2A Foundation today announced a research collaboration with Unravel Biosciences, Inc., an AI-enabled therapeutics company established to advance drugs for complex diseases.

  3. Insilico Medicine And Qilu Pharmaceutical Reach Near $120M Drug Development Collaboration To Accelerate Novel Cardiometabolic Therapies 1/27/2026

    Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

  4. Drug Farm Announces FDA Fast Track Designation For First-In-Class ALPK1 Inhibitor DF-003 For The Treatment Of ROSAH Syndrome 1/27/2026

    Drug Farm, a clinical-stage biopharmaceutical company advancing two novel small molecule drugs for ROSAH syndrome and hepatitis B, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DF-003, its investigational, first-in-class ALPK1 inhibitor, for the treatment of ROSAH syndrome, a rare, autosomal dominant autoinflammatory disease with no approved therapies.

  5. Mair Therapeutics Announces Scientific Collaboration With Radboud University To Advance TMEM175 Agonists For Parkinson's Disease 1/26/2026

    Mair Therapeutics, a Dutch biotechnology company pioneering lysosomal-targeted therapies for neurodegenerative diseases, today announced a scientific collaboration with Radboud University to accelerate the discovery of small-molecule agonists of TMEM175, a lysosomal ion channel genetically linked to Parkinson's disease.

  6. Lunai Bioworks Expands NIH-Funded AI Program Into Commercial Alcohol Use Disorder Drug Discovery 1/26/2026

    Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol withdrawal.

  7. Novaliq Receives FDA IND Clearance To Advance NOV05 In A Phase II Clinical Trial In Non-Infectious Anterior Uveitis 1/26/2026

    Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases.

  8. New Platform To Accelerate Cardiac Drug Development 1/22/2026

    Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated production of 3D cardiac microtissues.

  9. Ellipses In-Licenses First-In-Class B7H3 Antibody Drug Conjugate From China 1/22/2026

    Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd (“Innolake”) to develop a clinical stage first-in-class antibody drug conjugate (ADC).

  10. Voyager Enables Microgravity-Enabled Drug Discovery 1/22/2026

    Voyager Technologies announced a new contract with Space LiinTech to manifest a new payload to the International Space Station, advancing microgravity-enabled drug discovery.